Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 (IgG4) antibody, imsidolimab, to treat ...

New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...

AnaptysBio (NASDAQ:ANAB) stock maintained its Neutral rating and $19.00 price target from H.C. Wainwright. Currently trading ...

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing ...

The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

SPEVIGO is a novel, selective antibody that blocks the activation of the interleukin-36 r ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

A team from Nagoya University in Japan has identified previously unidentified gene variants that are associated with the development of generalized pustular psoriasis (GPP). The team's findings ...

Recent studies imply that acute generalized exanthematous pustulosis ... while Th-1-derived dermatoses, such as psoriasis and sarcoidosis, are ameliorated. AGEP, a neutrophile, cell-mediated ...